10.53

0.85% -0.08

Theravance Biopharma Inc (TBPH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$10.61

Aprire:

$10.49

Volume 24 ore:

13,013

Relative Volume:

0.05

Capitalizzazione di mercato:

$538.51M

Reddito:

$62.02M

Utile/perdita netta:

$-45.65M

Rapporto P/E:

-11.45

EPS:

-0.92

Flusso di cassa netto:

$-9.60M

1 W Prestazione:

-6.49%

1M Prestazione:

+18.07%

6M Prestazione:

+6.48%

1 anno Prestazione:

+22.61%

Intervallo 1D:

$10.46

$10.63

Intervallo di 1 settimana:

$10.46

$11.27

Portata 52W:

$7.44

$11.82

Theravance Biopharma Inc Stock (TBPH) Company Profile

Nome

Theravance Biopharma Inc

Settore

Healthcare (1174)

Industria

Biotechnology (661)

Telefono

650-808-6000

Indirizzo

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

TBPH's Discussions on Twitter

Confronta TBPH con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TBPH Theravance Biopharma Inc	10.54	538.51M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	456.19	113.97B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	520.13	52.15B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	302.00	40.16B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	580.28	35.45B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	272.12	27.80B	3.81B	-644.79M	-669.77M	-6.24

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-06	Downgrade	Leerink Partners	Outperform → Market Perform
2024-04-12	Iniziato	BTIG Research	Buy
2024-01-08	Downgrade	Evercore ISI	Outperform → In-line
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-11-05	Aggiornamento	JP Morgan	Underweight → Neutral
2021-09-15	Downgrade	JP Morgan	Overweight → Underweight
2021-08-25	Downgrade	Morgan Stanley	Overweight → Underweight
2021-08-24	Downgrade	Cowen	Outperform → Market Perform
2020-10-14	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Iniziato	JP Morgan	Overweight
2020-06-15	Iniziato	Morgan Stanley	Equal-Weight
2020-05-13	Iniziato	Cowen	Outperform
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-06	Aggiornamento	Robert W. Baird	Underperform → Neutral
2019-10-29	Iniziato	H.C. Wainwright	Buy
2018-03-29	Ripresa	Piper Jaffray	Overweight
2017-08-17	Iniziato	Evercore ISI	Outperform
2017-06-16	Iniziato	Cantor Fitzgerald	Overweight
2017-05-11	Reiterato	Needham	Buy
2016-12-21	Iniziato	Needham	Buy
2016-11-03	Iniziato	Piper Jaffray	Overweight
2016-10-12	Downgrade	Robert W. Baird	Neutral → Underperform
2016-08-03	Downgrade	BofA/Merrill	Neutral → Underperform
2016-06-20	Iniziato	Guggenheim	Buy
2016-06-20	Reiterato	Leerink Partners	Outperform
2016-05-12	Iniziato	Leerink Partners	Outperform
2016-05-05	Downgrade	BofA/Merrill	Buy → Neutral
2015-02-03	Aggiornamento	Robert W. Baird	Underperform → Neutral

Mostra tutto

Theravance Biopharma Inc Borsa (TBPH) Ultime notizie

Jun 09, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 09, 2025

Jun 06, 2025

Theravance and Mylan settle patent dispute with Eugia Pharma - MSN

Jun 06, 2025

theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa

Jun 06, 2025

Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha

Jun 06, 2025

Theravance BiopharmaTheravance And Mylan Enter Settlement Agreement With EugiaSEC Filing - marketscreener.com

Jun 06, 2025

Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks

Jun 06, 2025

theravance biopharma settles patent litigation with eugia pharma - Investing.com

Jun 06, 2025

Jun 04, 2025

(TBPH) Investment Analysis - news.stocktradersdaily.com

Jun 04, 2025

Theravance Biopharma Sells Remaining Trelegy Royalties to GSK for $225 Million - Global Legal Chronicle

Jun 04, 2025

Jun 03, 2025

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - sharewise

Jun 03, 2025

ProShare Advisors LLC Takes Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 03, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC - Defense World

Jun 03, 2025

Jun 02, 2025

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - marketscreener.com

Jun 02, 2025

Theravance Biopharma Sells Trelegy Royalty Interest to GSK - TipRanks

Jun 02, 2025

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in T - GuruFocus

Jun 02, 2025

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - Eagle-Tribune

Jun 02, 2025

Ameriprise Financial Inc. Cuts Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 02, 2025

Jun 01, 2025

Nuveen Asset Management LLC Buys 48,635 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jun 01, 2025

May 30, 2025

Deutsche Bank AG Purchases 15,608 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 30, 2025

Jane Street Group LLC Has $493,000 Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 30, 2025

May 29, 2025

Bank of America Corp DE Increases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 29, 2025

May 28, 2025

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - Barchart.com

May 28, 2025

May 25, 2025

(TBPH) On The My Stocks Page - news.stocktradersdaily.com

May 25, 2025

May 23, 2025

Northern Trust Corp Has $3.67 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 23, 2025

May 21, 2025

The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance

May 21, 2025

May 20, 2025

Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine - Investing.com Canada

May 20, 2025

May 16, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by StockNews.com - Defense World

May 16, 2025

May 15, 2025

When (TBPH) Moves Investors should Listen - news.stocktradersdaily.com

May 15, 2025

May 13, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conf - GuruFocus

May 13, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune

May 13, 2025

Price T Rowe Associates Inc. MD Buys 9,315 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 13, 2025

Dimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 13, 2025

May 12, 2025

We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st

May 12, 2025

May 10, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at th - GuruFocus

May 09, 2025

Theravance Biopharma, Inc. Announces Ampreloxetine Presentations At the International MSA Congress - marketscreener.com

May 09, 2025

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - TradingView

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - Stock Titan

May 09, 2025

Theravance Biopharma: Promising Future with Strong Product Pipeline and Market Expansion - TipRanks

May 09, 2025